• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
Home
  • Research
  • Biotech
    • Clinical Data
    • Venture Capital
    • Deals
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending Topics
    • Cell & Gene Therapy
    • COVID-19
  • Podcasts
  • Resources
    • Events
    • Webinars
    • Podcasts
    • Whitepapers
  • Subscribe
Search Icon
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Research
  • Biotech
    • Clinical Data
    • Venture Capital
    • Deals
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending Topics
    • Cell & Gene Therapy
    • COVID-19
  • Podcasts
  • Resources
    • Events
    • Webinars
    • Podcasts
    • Whitepapers
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events

Medicago

Biotech

Next-gen COVID shots need differentiation, pan-variant potential

Next-gen COVID shots from Sanofi/GSK, Gritstone, Valneva and others will need to be different from current shots, plus easy to scale up in production.
Annalee Armstrong , Kyle LaHucik Jan 24, 2022 10:53am

GlaxoSmithKline, Medicago hit 75% efficacy against delta

Dec 7, 2021 7:00am

Medicago, GSK post data on plant-derived COVID-19 vaccine

May 18, 2021 5:21am

GSK kick-starts phase 3 Medicago-partnered COVID vaccine test

Mar 16, 2021 8:30am

GlaxoSmithKline pens COVID-19 vaccine pact with Medicago

Jul 7, 2020 8:55am
Home
  • Connect
    • The Team
    • Advertise
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
  • ©2022 Questex LLC All rights reserved.
  • Terms of use
  • Privacy Policy